129 related articles for article (PubMed ID: 22335027)
1. The treatment of uterine leiomyosarcoma: clinical outcomes of 18 cases and the effectiveness of chemotherapy.
Matoda M; Takeshima N; Nomura H; Kino M; Omatsu K; Iwase H; Umayahara K; Takizawa K
Eur J Gynaecol Oncol; 2011; 32(6):647-50. PubMed ID: 22335027
[TBL] [Abstract][Full Text] [Related]
2. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide.
Hirota Y; Miyamura K; Hayata T; Miyakawa I
Gynecol Obstet Invest; 1997; 44(1):70-2. PubMed ID: 9251960
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
Pautier P; Genestie C; Fizazi K; Morice P; Mottet C; Haie-Meder C; Le Cesne A; Lhommé C
Int J Gynecol Cancer; 2002; 12(6):749-54. PubMed ID: 12445254
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
8. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.
Pearl ML; Inagami M; McCauley DL; Valea FA; Chalas E; Fischer M
Int J Gynecol Cancer; 2002; 12(6):745-8. PubMed ID: 12445253
[TBL] [Abstract][Full Text] [Related]
9. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
[TBL] [Abstract][Full Text] [Related]
10. Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
Minobe S; Todo Y; Suzuki Y; Aoyagi Y; Umazume T; Okamoto K; Kato H
J Obstet Gynaecol Res; 2011 Jun; 37(6):645-9. PubMed ID: 21375676
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.
Hawkins RE; Wiltshaw E; Mansi JL
Cancer Chemother Pharmacol; 1990; 26 Suppl():S26-9. PubMed ID: 2347045
[TBL] [Abstract][Full Text] [Related]
12. High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma.
Yeh KH; Lu YS; Hsiao CH; Cheng AL
Anticancer Res; 2003; 23(6D):5133-7. PubMed ID: 14986591
[TBL] [Abstract][Full Text] [Related]
13. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
[TBL] [Abstract][Full Text] [Related]
14. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
15. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
[TBL] [Abstract][Full Text] [Related]
16. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Beecham J; Homesley H; Yordan E
J Clin Oncol; 1991 Nov; 9(11):1962-6. PubMed ID: 1941054
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
Raut CP; Nucci MR; Wang Q; Manola J; Bertagnolli MM; Demetri GD; Morgan JA; Muto MG; Fletcher CD; George S
Eur J Cancer; 2009 Nov; 45(16):2818-24. PubMed ID: 19647426
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study.
Currie J; Blessing JA; Muss HB; Fowler J; Berman M; Burke TW
Gynecol Oncol; 1996 Apr; 61(1):27-30. PubMed ID: 8626112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
